Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment
The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...
Takeda
Takeda Pharmaceutical’s Teduglutide Filed for Marketing Approval in China
The Center for Drug Evaluation (CDE) website in China indicates that Japan-based Takeda Pharmaceutical Co.,...
Takeda’s Obizur Accepted by China’s NMPA for Acquired Hemophilia A Treatment
Takeda Pharmaceutical Co., Ltd’s (NYSE: TAK, TYO: 4502) China unit announced that a New Drug...